FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to compound of formula (I): or its salt, solvate, tautomer or N-oxide, where said compound has enantiomeric purity at least 80%.
EFFECT: described are methods of obtaining (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)phenyl]ethanol, novel intermediate compounds and methods of obtaining novel intermediate compounds.
18 cl, 10 ex
Title | Year | Author | Number |
---|---|---|---|
COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | 2006 |
|
RU2387653C2 |
TRIAZOLES USED AS PROTEIN KINASE INHIBITORS | 2005 |
|
RU2393155C2 |
COMPOUNDS AND COMPOSITIONS AS PROTEINKINASE INHIBITORS | 2006 |
|
RU2411242C2 |
TETRAHYDROPYRANYL AMINO-PYRROLOPYRIMIDINONE AND METHODS OF ITS USE | 2020 |
|
RU2747991C1 |
INHIBITOR OF CASEIN KINASE 1 DELTA AND CASEIN KINASE 1 ? | 2011 |
|
RU2562833C2 |
TETRAHYDROPYRANYL AMINO-PYRROLOPYRIMIDINONE AND METHODS FOR USE THEREOF | 2015 |
|
RU2715421C2 |
TERT-BUTYL-N-[2-{4-[6-AMINO-5-(2,4-DIFLUOROBENZOYL)-2-OXOPYRIDIN-1(2H)-YL]-3,5-DIFLUOROPHENYL}ETHYL]-L-ALANINATE OR SALT, HYDRATE OR SOLVATE THEREOF | 2013 |
|
RU2676329C2 |
NEW COMPOUNDS | 2016 |
|
RU2747645C2 |
BIGETEROARYL-SUBSTITUTED 1,4-BENZODIAZEPINES AND WAYS OF THEIR USE FOR CANCER TREATMENT | 2016 |
|
RU2747644C2 |
COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | 2006 |
|
RU2383545C2 |
Authors
Dates
2014-08-27—Published
2008-03-14—Filed